Ovarian cancer: Risk factors, treatment and management

British Journal of Nursing

Volumn 22, Issue 17 SUPPL., 2013, Pages

  Rooth, Carolyn ^a,b  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b MILTON KEYNES GENERAL HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; Gynaecological surgery; Gynaecology; Oncology; Ovarian cancer; Patient support

Indexed keywords

EID: 84885137862     PISSN: 09660461     EISSN: None     Source Type: Journal    
DOI: 10.12968/bjon.2013.22.sup17.s23     Document Type: Article

References (85)

1. Akdeniz N, Kuyumcuoǧlu U, Kale A, Erdemoǧlu M, Caca F (2009) Risk of malignancy index for adnexal masses. Eur J Gynaecol Oncol 30(2):178-80
2. Armstrong DK, Bundy B, Wenzel L, et al (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354(1):34-43
3. Aslam N, Tailor A, Lawton F, Carr J, Savvas M, Jurkovic D (2000) Prospective evaluation of three different models for the pre-operative diagnosis of ovarian cancer. BJOG 107(11):1347-53
4. Bankhead C, Collins C, Stokes-Lampard H, Rose P, Wilson S, Clements A, et al (2008) Identifying symptoms of ovarian cancer: a qualitative and quantitative study. BJOG 115(8):1008-14
5. Barroilhet L, Vitonis A, Shipp T, Muto M, Benacerraf B (2013) Sonographic predictors of ovarian malignancy. J Clin Ultrasound 41(5):269-74
6. Benedet JL, Bender H, Jones H 3rd, et al (2000) FIGO Staging classifications and clinical practice guidelines of gynaecological cancers. Int J Gynaecol Obstet 70(2):209-62
7. Beral V, Bull D, Green J, Reeves G (2007) Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 369(9574):1703-10
8. Bristow RE, Tomacruz RS, Armstrong DK, et al (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20(5):1248-59
9. Cancer Research UK (2011) Cancer Stats: Ovarian Cancer-UK. March 2011. Cancer Research UK, London
10. Cancer Research UK (2012a) CancerStats briefing. Cancer in the UK. May 2012. CancerResearch UK. http://info.cancerresearchuk.org/cancerstats (accessed 20 August 2013)
11. Cancer Research UK (2012b) Cancer death rates set to drop 17 per cent by 2030. Cancer Research UK Press Release, 25 September 2012. http://tinyurl.com/ k2egq4m (accessed 20 August 2013)
12. Cancer Research UK (2013) Ovarian Cancer Key Facts. http://tinyurl.com/ mfw7n5w (accessed 20 August 2013)
13. Cannistra SA, Matulonis UA, Penson RT, et al (2007) Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25(33):5180-6
14. Clark TG, Stewart ME, Altman DG, Gabra H, Smyth JF (2001) A prognostic model for ovarian cancer. Br J Cancer 85(7):944-52
15. Department of Health (DH) and Macmillan (2010) National Cancer Action Team Quality in Nursing Excellence in Cancer Care: The Contribution of the Clinical Nurse Specialist. DoH, London
16. DH (2012) Cancer Patient Experience Survey 2011/12: National Report. DH, London
17. DH (2007) Delivering the Cancer Reform Strategy. DH, London
18. Edwards SJ, Barton S, Thurgar E, et al (2012) Bevacizumab for the treatment of recurrent advanced ovarian cancer: a single technology appraisal. BMJ-TAG, London
19. Eriksson JH and Frazier SR (2000) Epithelial cancers of the ovary and fallopian tube. In: Moore-Higgs GJ, ed. Women and Cancer: a Gynaecologic Oncology Nursing Perspective. Jones and Bartlett, Massachussetts
20. European Medicines Agency (2012) Avastin. Annex 1. Summary of product character istics. http://tinyurl.com/lkb4zcz (accessed 20 August 2013)
21. Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46(4):765-81
22. Ferrandina G, Sallustio G, Fagotti A, et al (2009) Role of CT scan-based and clinical evaluation in the preoperative prediction of optimal cytoreduction in advanced ovarian cancer: a prospective trial. Br J Cancer 101(7):1066-73
23. FIGO Committee on Gynecologic Oncology (2000). Staging classifications and clinical practice guidelines of gynaecological cancers, 2000. FIGO, London
24. Flynn PM, Paul J, Cruickshank DJ, Scottish Gynaecological Cancer Trials Group (2002) Does the interval from primary surgery to chemotherapy influence progression-free survival in ovarian cancer? Gynecol Oncol 86(3):354-7
25. Gayther SA, Pharoah PD (2010) The inherited genetics of ovarian and endometrial cancer. Curr Opin Genet Dev 20(3):231-8
26. Goff BA, Mandel LS, Drescher C W, et al (2007) Development of an ovarian cancer symptom index: possibilities for early detection. Cancer 109(2):221-7
27. Granstrom C, Sundquist J, Hemminki K (2008) Population attributable fractions for ovarian cancer in Swedish women by morphological type. Br J Cancer 98(1):199-205
28. Hamilton W, Peters TJ, Bankhead C, Sharp D (2009) Risk of ovarian cancer in women with symptoms in primary care: population based case-control study. BMJ 339:b2998
29. Hennessy BT, Coleman RL, Markman M (2009) Ovarian cancer. Lancet 374(9698):1371-82
30. Houck K, Nikrui N, Duska L, et al (2000) Borderline tumors of the ovary: correlation of frozen and permanent histopathologic diagnosis. Obstet Gynaecol 95(6 Pt 1):839-43
31. Iyer VR, Lee SI (2010) MRI, CT, and PET/CT for ovarian cancer detection and adnexal lesion characterization. Am J Roentgenol 194(2):311-21
32. Jensen A, Sharif H, Frederiksen K, Kjaer SK (2009) Use of fertility drugs and risk of ovarian cancer: Danish Population Based Cohort Study. BMJ 338:b249
33. Jordan SJ, Whiteman DC, Purdie DM, et al (2006) Does smoking increase risk of ovarian cancer? A systematic review. Gynecol Oncol 103(3):1122-9
34. Kagan R (2012) Surgical menopause: still confused after all these years. Menopause 19(5):491-3
35. Kashyap S, Moher D, Fung M F, Rosenwaks Z (2004) Assisted reproductive technology and the incidence of ovarian cancer: a meta-analysis. Obstet Gynecol 103(4):785-94
36. Kauff ND, Domchek SM, Friebel TM, et al (2008) Risk-reducing salpingooophorectomy for the prevention of BRCA1-and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 26(8):1331-7
37. Kurian AW, Balise RR, McGuire V, Whittemore AS (2005) Histologic types of epithelial ovarian cancer: have they different risk factors? Gynecol Oncol 96(2):520-30
38. Lawrie TA, Medeiros LR, Rosa DD, et al (2013) Laparoscopy versus laparotomy for FIGO stage I ovarian cancer. Cochrane Database Syst Rev 28 Feb. 2013
39. MacDonald S, Macleod U, Mitchell E (2004) Factors Influencing Patient and Primary Care Delay in the Diagnosis of Cancer (Project M0005101440). Final report to the Department of Health. University of Glasgow, Glasgow
40. McCluggage WG (2010) The pathology of and controversial aspects of ovarian borderline tumours. Curr Opin Oncol 22(5):462-72
41. McGee P and Castledine G (2003) Advanced Nursing Practice. 2nd edition. Blackwell Publishing Ltd, Oxford
42. McLaughlin JR, Risch HA, Lubinski J, et al (2007) Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol 8(1):26-34
43. Monk BJ, Han E, Josephs-Cowan CA, et al (2006) Bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol Oncol 102(2):140-4
44. NHS (2010) National Cancer Patient Experience Survey Programme-2010 national survey report. DoH, London
45. National Institute for Health and Care Excellence (NICE) (2005) Guidance on the use of paclitaxel in the treatment of ovarian cancer. Technology appraisal guidance (TA55, 2003). NICE, London
46. NICE (2011) Ovarian cancer. Clinical guideline (CG122). NICE, London
47. NICE (2012) Quality standard for ovarian cancer (QS18). NICE, London
48. NICE (2013a) Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab (TA285). http://www.nice.org.uk/guidance/index.jsp?action= byID&o=14170 (accessed 20 August 2013)
49. NICE (2013b) Bevacizumab in combination with paclitaxel and carboplatin, as first-line treatment for advanced ovarian cancer (TA284). http://guidance. nice.org.uk/TA284
50. National Patient Safety Agency (2010) Delayed diagnosis of cancer: Thematic review. http://www.nrls.npsa.nhs.uk/EasySiteWeb/getresource.axd? AssetID=69895&1 (accessed 20 August 2013)
51. Norton T, Manne S, Rubin S, et al (2005) Ovarian cancer patients' psychological distress: the role of physical impairment, perceived unsupportive family and friend behaviors, perceived control, and self-esteem. Health Psychol 24(2):143-5
52. Nursing and Midwifery Council (NMC) (2008) The code: Standards of conduct, performance and ethics for nurses and midwives. NMC, London
53. Odicino F, Pecorelli S, Zigliani L, Creasman WT (2008) History of the FIGO cancer staging system. Int J Gynaecol Obstet 101(2):205-10
54. Ovacome (2013) Defining Quality in Ovarian Cancer Services: the Patient Perspective. Ovacome: the Ovarian Cancer Support Network. Roche, London
55. Ozols R F, Bundy BN, Greer BE, et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21(17):3194-200
56. Parmar M K B, Ledermann JA, Colombo N, et al (2003) Paclitaxel plus platinumbased chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. The ICON and AGO Collaborators. Lancet 361(9375):2099-106
57. Pasalich M, et al (2013) Reproductive factors for ovarian cancer in southern Chinese women. J Gynecol Oncol 24(2):135-40
58. Piccart MJ, James K, Cassidy J, Mangioni C, Simonsenm E (2000) Randomized intergroup trial of Cisplatin-Paclitaxel versus Cisplatin-Cyclophosphamide in women with advanced epithelial ovarian cancer: three year results. J Natl Cancer Inst 92(9):699-708
59. Pinato DJ, Graham J, Gabra H, Sharma R (2013) Evolving concepts in the management of drug resistant ovarian cancer: dose dense chemotherapy and the reversal of clinical platinum resistance. Cancer Treat Rev 39(2):153-60
60. Power J, Brown L, Ritvo P (2008) Af qualitative study examining psychosocial distress, coping, and social support across the stages and phases of epithelial ovarian cancer. Health Care Women Int 29(4):366-83
61. Purdie DM, Webb PM, Siskind V, Bain CJ, Green AC (2003) The different etiologies of mucinous and nonmucinous epithelial ovarian cancers. Gynecol Oncol 88 i (1 Pt 2): S145-8
62. Radwany SM and von Gruenigen VE (2012) Palliative and end-of-life care for patients with ovarian cancer. Clin Obstet Gynecol 55(1):173-84
63. Riman T, Nilsson S, Persson IR (2004) Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies. Acta Obstet Gynecol Scand 83(9):783-95
64. Robb K, Stubbings S, Ramirez A, et al (2009) Public awareness of cancer in Britain: a population-based survey of adults. Br J Cancer 101(Suppl 2):S18-23
65. Rodriguez A, Wun T, Chew H, Zhou H, Harvey D and White R (2007) Venous thromboembolism in ovarian cancer. Gynecol Oncol 105(3):784-90
66. Salehi F, Dunfield L, Phillips K P, Krewski D, Vanderhyden BC (2008) Risk factors for ovarian cancer: an overview with emphasis on hormonal factors. J Toxicol Environ Health B Crit Rev 11(3-4):301-21
67. Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R (2009) EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer 45(6):931-91
68. Sayasneh A, Kaijser J, Preisler J, et al (2013) A multicenter prospective external validation of the diagnostic performance of IOTA simple descriptors and rules to characterize ovarian masses. Gynecol Oncol 130(1):140-6
69. Schouten LJ, Rivera C, Hunter DJ, et al (2008) Height, body mass index, and ovarian cancer: a pooled analysis of 12 cohort studies. Cancer Epidemiol Biomarkers Prev 17(4):902-12
70. Schorge JO, McCann C, Del Carmen MG (2010) Surgical debulking of ovarian cancer: what difference does it make? Rev Obstet Gynecol 3(3):111-17
71. Schwartz S and Williams D (2002) Psychological aspects of gynecologic surgery. CME J Gynaecol Oncol 7:268-79
72. SIGN (2003) Guidance 75: Epithelial Ovarian Cancer, October 2003, Scottish Intercollegiate Guidelines Network. SIGN, Edinburgh
73. Skeel RT (2003) Handbook of Cancer Chemotherapy. 6th edn. Lippincott Williams & Wilkins
74. Sturgeon C (2002) Practice guidelines for tumour markers used in the clinic. Clin Chem 48(8):1151-9
75. Sueblinvong T, Carney ME (2009) Current understanding of risk factors for ovarian cancer. Curr Treat Options Oncol 10(1-2):67-81
76. Suh KS, Sang W P, Castro A, et al (2010) Ovarian cancer biomarkers for molecular biosensors and translational medicine. Expert Rev Mol Diagn 10(8):1069-83
77. Tingulstad S, Hagen B, Skjeldestad FE, et al (1996) Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses. Br J Obstet Gynaecol 103(8):826-31
78. Togashi (2003) Ovarian cancer: the clinical role of US, CT and MRI. Eur Radiol 13(Suppl 4):L87-104
79. Trimbos B, Timmers P, Pecorelli S (2010) Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial. J Natl Cancer Inst 102(13):982
80. Tworoger SS, Fairfield KM, Colditz GA, Rosner BA, Hankinson SE (2007) Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. Am J Epidemiol 166(8):894-901
81. Ushijima K (2009) Current status of gynecologic cancer in Japan. J Gynecol Oncol 20(2):67-71
82. Vernooij F, Heintz P, Witteveen E, Van der Graaf Y (2007) The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review. Gynaecol Oncol 105(3):801-12
83. Watson P, Vasen H F, Mecklin J P, et al (2008) The risk of extra-colonic, extra endometrial cancer in the Lynch syndrome. Int J Cancer 123(2):444-9
84. Whittemore AS, Balise RR, Pharoah P D P, et al (2004) Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. Br J Cancer 91(11):1911-15
85. Winter-Roach BA, Kitchener HC, Lawrie TA (2012) Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev 14(3):CD004706.